CG Oncology, Inc.
CGONHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CG Oncology, Inc. focuses on Biotechnology services and products. CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company carries a $6.62B market cap, placing it firmly in the mid-cap category. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Market Cap
$6.62B
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
-24.72
EPS (TTM)
$-2.69
EPS (Fwd)
$-3.02
ROE
-26.4%
ROA
-17.7%
Cash
$1.03B
Total Debt
$8.8M
Free CF
-$113.7M
52W Change
123.1%
Annual Financials
Cash vs Debt
Where CGON stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CGON finished 15.04% above its 150-day moving average ($65.94) and 25.22% above its 200-day moving average ($60.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGON overbought or oversold?
At the September 2, 2026 close, CGON's RSI(14) was 47.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.03B in cash and $8.8M in debt, CGON maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$113.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -26.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $191K (2022) to $4.0M (2025), reflecting a 2015% increase over the period.
With a beta below 0.7, CG Oncology, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, CGON has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence CG Oncology, Inc.'s trajectory.